# LENZ Therapeutics, Inc.: financial statements, quarterly

LENZ · Nasdaq · CIK 1815776 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lenz.md) · [Financials](/companies/lenz/financials.md) · [Filings](/companies/lenz/filings.md) · [Insiders](/companies/lenz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lenz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001815776-25-000056.md) | [0.0](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | [0.0](/filings/0001815776-26-000037.md) | [5.0](/filings/0001815776-26-000052.md) | [12.5](/filings/0001815776-25-000071.md) | [1.6 d](/filings/0001815776-26-000011.md) | [1.9](/filings/0001815776-26-000037.md) | [5.5](/filings/0001815776-26-000052.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001815776-26-000037.md) | [0.0](/filings/0001815776-26-000052.md) | not reported | not reported | [1.1](/filings/0001815776-26-000037.md) | [0.3](/filings/0001815776-26-000052.md) |
| Research and development | $m | [17.0](/filings/0001815776-24-000071.md) | [19.5 d](/filings/0001815776-25-000019.md) | [10.5](/filings/0001815776-25-000032.md) | [6.9](/filings/0001815776-25-000056.md) | [6.5](/filings/0001815776-25-000071.md) | [5.9 d](/filings/0001815776-26-000011.md) | [5.8](/filings/0001815776-26-000037.md) | [9.1](/filings/0001815776-26-000052.md) | [3.8](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | [0.0](/filings/0001815776-26-000037.md) | [0.0](/filings/0001815776-26-000052.md) |
| Selling, general and administrative | $m | [2.9](/filings/0001815776-24-000071.md) | [5.5 d](/filings/0001815776-25-000019.md) | [5.6](/filings/0001815776-25-000032.md) | [7.4](/filings/0001815776-25-000056.md) | [6.5](/filings/0001815776-25-000071.md) | [9.4 d](/filings/0001815776-26-000011.md) | [11.1](/filings/0001815776-26-000037.md) | [12.8](/filings/0001815776-26-000052.md) | [27.6](/filings/0001815776-25-000071.md) | [39.6 d](/filings/0001815776-26-000011.md) | [45.0](/filings/0001815776-26-000037.md) | [39.4](/filings/0001815776-26-000052.md) |
| Operating income | $m | [(19.9)](/filings/0001815776-24-000071.md) | [(25.0) d](/filings/0001815776-25-000019.md) | [(16.1)](/filings/0001815776-25-000032.md) | [(14.4)](/filings/0001815776-25-000056.md) | [(12.9)](/filings/0001815776-25-000071.md) | [(15.2) d](/filings/0001815776-26-000011.md) | [(16.9)](/filings/0001815776-26-000037.md) | [(16.9)](/filings/0001815776-26-000052.md) | [(18.9)](/filings/0001815776-25-000071.md) | [(38.5) d](/filings/0001815776-26-000011.md) | [(44.1)](/filings/0001815776-26-000037.md) | [(34.2)](/filings/0001815776-26-000052.md) |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001815776-25-000056.md) | [0.0](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | not reported | [0.5](/filings/0001815776-26-000052.md) | [0.0](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | not reported | [0.0](/filings/0001815776-26-000052.md) |
| Net income | $m | [(18.9)](/filings/0001815776-24-000071.md) | [(23.7) d](/filings/0001815776-25-000019.md) | [(16.6)](/filings/0001815776-25-000071.md) | [(10.3)](/filings/0001815776-25-000071.md) | [(10.2)](/filings/0001815776-25-000071.md) | [(12.7) d](/filings/0001815776-26-000011.md) | [(14.6)](/filings/0001815776-26-000052.md) | [(14.9)](/filings/0001815776-26-000052.md) | [(16.7)](/filings/0001815776-25-000071.md) | [(35.9) d](/filings/0001815776-26-000011.md) | [(41.5)](/filings/0001815776-26-000052.md) | [(31.9)](/filings/0001815776-26-000052.md) |
| Diluted EPS | $ per share | [(9.62)](/filings/0001815776-24-000071.md) | not reported | [(3.53)](/filings/0001815776-25-000032.md) | [(0.40)](/filings/0001815776-25-000056.md) | [(0.38)](/filings/0001815776-25-000071.md) | not reported | [(0.53)](/filings/0001815776-26-000037.md) | [(0.53)](/filings/0001815776-26-000052.md) | [(0.59)](/filings/0001815776-25-000071.md) | not reported | [(1.32)](/filings/0001815776-26-000037.md) | [(1.02)](/filings/0001815776-26-000052.md) |
| Basic EPS | $ per share | [(9.62)](/filings/0001815776-24-000071.md) | not reported | [(3.53)](/filings/0001815776-25-000032.md) | [(0.40)](/filings/0001815776-25-000056.md) | [(0.38)](/filings/0001815776-25-000071.md) | not reported | [(0.53)](/filings/0001815776-26-000037.md) | [(0.53)](/filings/0001815776-26-000052.md) | [(0.59)](/filings/0001815776-25-000071.md) | not reported | [(1.32)](/filings/0001815776-26-000037.md) | [(1.02)](/filings/0001815776-26-000052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [183](/filings/0000950170-23-062942.md) | [35.1](/filings/0001815776-25-000019.md) | [200](/filings/0001815776-24-000042.md) | [84.0](/filings/0001815776-24-000060.md) | [41.0](/filings/0001815776-24-000071.md) | [20.2](/filings/0001815776-26-000011.md) | [23.0](/filings/0001815776-25-000032.md) | [37.6](/filings/0001815776-25-000056.md) | [25.4](/filings/0001815776-25-000071.md) | [25.2](/filings/0001815776-26-000052.md) | [24.8](/filings/0001815776-26-000037.md) | [24.2](/filings/0001815776-26-000052.md) |
| Current assets | $m | [239](/filings/0000950170-23-062942.md) | [67.2](/filings/0001815776-25-000019.md) | [217](/filings/0001815776-24-000042.md) | [199](/filings/0001815776-24-000060.md) | [221](/filings/0001815776-24-000071.md) | [212](/filings/0001815776-26-000011.md) | [198](/filings/0001815776-25-000032.md) | [214](/filings/0001815776-25-000056.md) | [207](/filings/0001815776-25-000071.md) | [301](/filings/0001815776-26-000052.md) | [268](/filings/0001815776-26-000037.md) | [233](/filings/0001815776-26-000052.md) |
| Total assets | $m | [266](/filings/0000950170-23-062942.md) | [70.4](/filings/0001815776-25-000019.md) | [217](/filings/0001815776-24-000042.md) | [203](/filings/0001815776-24-000060.md) | [224](/filings/0001815776-24-000071.md) | [215](/filings/0001815776-26-000011.md) | [201](/filings/0001815776-25-000032.md) | [217](/filings/0001815776-25-000056.md) | [211](/filings/0001815776-25-000071.md) | [306](/filings/0001815776-26-000052.md) | [273](/filings/0001815776-26-000037.md) | [237](/filings/0001815776-26-000052.md) |
| Current liabilities | $m | [12.5](/filings/0000950170-23-062942.md) | [18.5](/filings/0001815776-25-000019.md) | [18.9](/filings/0001815776-24-000042.md) | [8.6](/filings/0001815776-24-000060.md) | [7.7](/filings/0001815776-24-000071.md) | [10.4](/filings/0001815776-26-000011.md) | [8.6](/filings/0001815776-25-000032.md) | [10.4](/filings/0001815776-25-000056.md) | [16.3](/filings/0001815776-25-000071.md) | [21.2](/filings/0001815776-26-000052.md) | [25.8](/filings/0001815776-26-000037.md) | [17.2](/filings/0001815776-26-000052.md) |
| Total liabilities | $m | [62.2](/filings/0000950170-23-062942.md) | [19.7](/filings/0001815776-25-000019.md) | [19.2](/filings/0001815776-24-000042.md) | [9.7](/filings/0001815776-24-000060.md) | [8.7](/filings/0001815776-24-000071.md) | [11.2](/filings/0001815776-26-000011.md) | [9.2](/filings/0001815776-25-000032.md) | [11.0](/filings/0001815776-25-000056.md) | [16.8](/filings/0001815776-25-000071.md) | [21.5](/filings/0001815776-26-000052.md) | [26.0](/filings/0001815776-26-000037.md) | [17.3](/filings/0001815776-26-000052.md) |
| Shareholders' equity | $m | [(69.6)](/filings/0001815776-24-000071.md) | [(92.7)](/filings/0001815776-26-000011.md) | [198](/filings/0001815776-25-000071.md) | [193](/filings/0001815776-25-000071.md) | [215](/filings/0001815776-25-000071.md) | [204](/filings/0001815776-26-000052.md) | [192](/filings/0001815776-26-000052.md) | [206](/filings/0001815776-26-000052.md) | [194](/filings/0001815776-25-000071.md) | [284](/filings/0001815776-26-000052.md) | [246](/filings/0001815776-26-000052.md) | [219](/filings/0001815776-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.1) d](/filings/0001815776-24-000071.md) | [(21.0) d](/filings/0001815776-25-000019.md) | [(23.9)](/filings/0001815776-25-000032.md) | [(15.8) d](/filings/0001815776-25-000056.md) | [(10.6) d](/filings/0001815776-25-000071.md) | [(9.1) d](/filings/0001815776-26-000011.md) | [(16.0)](/filings/0001815776-26-000037.md) | [(11.5) d](/filings/0001815776-26-000052.md) | [(8.6) d](/filings/0001815776-25-000071.md) | [(33.0) d](/filings/0001815776-26-000011.md) | [(33.6)](/filings/0001815776-26-000037.md) | [(38.7) d](/filings/0001815776-26-000052.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001815776-24-000071.md) | [0.0 d](/filings/0001815776-25-000019.md) | [0.0](/filings/0001815776-25-000032.md) | [0.1 d](/filings/0001815776-25-000056.md) | [0.2 d](/filings/0001815776-25-000071.md) | [0.1 d](/filings/0001815776-26-000011.md) | [0.1](/filings/0001815776-26-000037.md) | [0.2 d](/filings/0001815776-26-000052.md) | [0.4 d](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | [0.0](/filings/0001815776-26-000037.md) | [0.0 d](/filings/0001815776-26-000052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.2](/filings/0000950170-23-062942.md) | [2.0](/filings/0001815776-24-000042.md) | [2.0](/filings/0001815776-24-000060.md) | [2.0](/filings/0001815776-24-000071.md) | [4.7](/filings/0001815776-25-000032.md) | [25.6](/filings/0001815776-25-000056.md) | [27.2](/filings/0001815776-25-000071.md) | [27.5](/filings/0001815776-26-000037.md) | [28.1](/filings/0001815776-26-000052.md) | [28.5](/filings/0001815776-25-000071.md) | [31.4](/filings/0001815776-26-000037.md) | [31.4](/filings/0001815776-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,420,343 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001815776-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.